Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$2.94 USD

2.94
302,018

-0.01 (-0.34%)

Updated Nov 4, 2024 03:59 PM ET

After-Market: $2.94 0.00 (0.00%) 4:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 90.91% and 11.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

by Zacks Equity Research

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised

by Zacks Equity Research

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised

by Zacks Equity Research

Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.

Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.

Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y

by Zacks Equity Research

Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.

Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.

Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion

by Zacks Equity Research

Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

by Zacks Equity Research

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe

by Zacks Equity Research

Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.

Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

by Zacks Equity Research

Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.

Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 950% and 11.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 53.1% Since Last Earnings Report?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y

by Zacks Equity Research

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

    Puma Biotech (PBYI) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Puma Biotech (PBYI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    by Zacks Equity Research

    Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y

    by Zacks Equity Research

    Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.

    Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Will Puma Biotech (PBYI) Report Negative Q4 Earnings? What You Should Know

    by Zacks Equity Research

    Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?